NeoVista is developing a radiation therapy device for treating of the wet form of Age-related Macular Degeneration (ARMD), one of the leading causes of blindness in the world. NeoVista is currently conducting clinical trials under an Investigational Device Exemption approved by the FDA.
NeoVista has completed A, B, and C rounds of funding, raising a total of $53.1 million.
38875 Cherry Street
Newark, CA 94560